Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review.

Abdolreza Haghpanah Fatemeh Masjedi Mehdi Salehipour Alireza Hosseinpour Jamshid Roozbeh Anahita Dehghani

Published in: Prostate cancer and prostatic diseases (2021)

Based on the current findings, SARS-CoV-2 can possibly damage the prostate and worsen BPH and its related LUTS through ACE2 signaling, AR-related mechanisms, inflammation, and metabolic derangement. We encourage future studies to investigate the possible role of COVID-19 in the progression of BPH-related LUTS and examine the prostatic status in susceptible patients with relevant available questionnaires (e.g., IPSS) and serum biomarkers (e.g., PSA).

Keyphrases

benign prostatic hyperplasia
lower urinary tract symptoms
sars cov
coronavirus disease
prostate cancer
oxidative stress
chronic obstructive pulmonary disease
depressive symptoms
angiotensin converting enzyme
extracorporeal membrane oxygenation
psychometric properties